COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,870 Articles (22,568 medRxiv, 8,302 bioRxiv)

Most recent first Previous |  Page 2193: Articles 21921-21930  | Next

Monitoring SARS-CoV-2 circulation and diversity through community wastewater sequencing
Izquierdo Lara, R. W., Elsinga, G., Heijnen, L., Oude Munnink, B. B., Schapendonk, C. M. E., Nieuwenhuijse, D., Kon, M., Lu, L., Aarestrup, F. M., Lycett, S., Medema, G., Koopmans, M. P. G., de Graaf, M.
10.1101/2020.09.21.20198838 — Posted: 2020-09-22
Epidemiological characteristics of COVID-19 cases in non-Italian nationals notified to the Italian surveillance system
Fabiani, M., Mateo-Urdiales, A., Andrianou, X., Bella, A., Del Manso, M., Bellino, S., Rota, M. C., Boros, S., Vescio, M. F., D'Ancona, F. P., Siddu, A., Punzo, O., Filia, A., Brusaferro, S., Rezza, G., Dente, M. G., Declich, S., Pezzotti, P., Riccardo, F.
10.1101/2020.09.22.20199398 — Posted: 2020-09-22
Reorganization of Substance Use Treatment and Harm Reduction Services during the COVID-19 Pandemic: A Global Survey
Radfar, S. R., De Jong, C. A. J., Farhoudian, A., Ebrahimi, M., Rafei, P., Vahidi, M., Yunesian, M., Kouimtsidis, C., Arunogiri, S., Massah, O., Deylamizadeh, A., Brady, K. T., Busse, A., ISAM-PPIG Global Survey Consortium, , Potenza, M. N., Ekhtiari, H., Baldacchino, A. M.
10.1101/2020.09.21.20199133 — Posted: 2020-09-22
Limits and opportunities of SARS-CoV-2 antigen rapid Tests: an experience based perspective
Lusebrink, J., Schildgen, O., Schildgen, V.
10.1101/2020.09.22.20199372 — Posted: 2020-09-22
The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes.
AlMadhi, M., Abdulrahman, A., AlAwadhi, A., Rabaan, A., AlQahtani, M.
10.1101/2020.09.22.20199422 — Posted: 2020-09-22
Treatment of Moderate to Severe Respiratory COVID-19--A Cost-Utility Analysis
Congly, S. E., Varughese, R. A., Brown, C. E., Clement, F. M., Saxinger, L.
10.1101/2020.09.21.20199182 — Posted: 2020-09-22
COVID-19 outbreak in Mauritius: Logistic growth and SEIR modelling with quarantine and an effective reproduction number
Gehin, A., Goorah, S., Moheeput, K., Ramchurn, S.
10.1101/2020.09.22.20199364 — Posted: 2020-09-22
Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia.
Massey, R.
10.1101/2020.09.17.20190033 — Posted: 2020-09-22
Experiences of receiving and providing maternity care during the COVID-19 Pandemic in Australia: a five-cohort cross-sectional comparison
Bradfield, Z., Wynter, K., Hauck, Y., Vasilevski, V., Kuliukas, L., Wilson, A., Szabo, R. A., Homer, C., Sweet, L.
10.1101/2020.09.22.20199331 — Posted: 2020-09-22
An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.
Zaidman, D., Gehrtz, P., Filep, M., Fearon, D., Prilusky, J., Duberstein, S., Cohen, G., Owen, D., Resnick, E., Strain-Damerell, C., Lukacik, P., Covid-Moonshot Consortium, , Barr, H., A. Walsh, M., von Delft, F., London, N.
10.1101/2020.09.21.299776 — Posted: 2020-09-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).